Gabapentin Tablet
Product Images NDC 68071-5310

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-5310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5310 9)

Gabapentin 800 mg tablets packaging label from NuCare Pharmaceuticals, Inc. The label indicates 90 tablets per bottle. It includes dosage strength, product number P1293090, NDC 68071-5310, and states RX only. The label also features manufacturing details, storage instructions at controlled temperature 68-77°F, and warnings to keep out of reach of children.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) is shown. It accounts for age in years, weight in kilograms, serum creatinine in mg/dL, and includes an adjustment factor of 0.85 for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

Line graph showing mean pain scores over an 8-week period comparing placebo and gabapentin at 3600 mg/day. The x-axis represents weeks including a 4-week dose titration and 4-week fixed dose period, and the y-axis shows mean pain scores from 0 to 10. Gabapentin demonstrates a decreasing pain score trend compared to placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

Line graph showing mean pain scores over a 7-week period for placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score values ranging from 0 to 10. Both gabapentin doses show a decrease in mean pain scores compared to placebo over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at different dosages across two studies. The y-axis shows percentage from 0% to 100%. Study 1 compares PBO (12%) and GBP 3600 mg (29%). Study 2 compares PBO (14%), GBP 1800 mg (32%), and GBP 2400 mg (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A chart depicting differences in percent on the y-axis against daily dose in mg on the x-axis for Gabapentin. It shows data points from three studies labeled as Study a, Study b, and Study c represented by different symbols and shading at doses of approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure diagram of Gabapentin showing its molecular arrangement with a cyclohexane ring and attached amino and carboxylic acid groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.